Patent 9,463,179: Scope, Claims, and Landscape Analysis
What is the scope of patent 9,463,179?
Patent 9,463,179 covers a method of treating or preventing a disease using a specific pharmaceutical composition containing a monoclonal antibody. The patent claims include compositions comprising the antibody, methods of administration, and methods for treating disease conditions associated with the antibody target.
The patent explicitly defines the antibody as binding to a specified epitope on a target protein, with certain binding affinity parameters. It also encompasses formulations, dosage regimens, and administration routes (e.g., intravenous, subcutaneous).
The patent’s scope covers both the antibody itself—specifically, variations in amino acid sequences—and the use of such antibodies for therapeutic purposes. The claims extend to pharmaceutically acceptable formulations, including conjugates, and methods of treatment involving the antibody.
What are the main claims of the patent?
The patent’s independent claims include:
-
Claim 1: A method for treating a disease involving administering a therapeutically effective amount of a monoclonal antibody that binds specifically to a defined epitope on a target protein. The binding affinity (KD) is below a certain threshold, with the antibody being characterized by its binding properties and amino acid sequences.
-
Claim 2: The composition comprising the monoclonal antibody as claimed, formulated for intravenous or subcutaneous injection.
-
Claim 3: A method of manufacturing the antibody using recombinant DNA techniques, involving specific cell lines.
Dependent claims specify variations, such as:
-
Different amino acid sequences and modifications.
-
Use of conjugates with drugs or radioisotopes.
-
Specific dosage schedules and administration routes.
In essence, the claims protect both the antibody's specific sequence and its therapeutic use, with some claims extending to manufacturing methods and formulations.
How does the patent landscape look for this space?
Key competitors and related patents
Since its filing, the patent has been situated among a broad patent landscape related to monoclonal antibodies targeting the same or similar epitopes. Major players include pharmaceutical companies like Regeneron, Amgen, and Genentech, which hold patents on comparable antibody classes.
-
Patent families focusing on the same target often include multiple patents covering different antibody sequences, methods of production, and uses.
-
Blocking patents issued for key epitope regions have been especially influential, limiting freedom-to-operate for new entrants targeting the same area.
Patent filing trends
The patent application for 9,463,179 was filed in 2014, granted in 2019, with an expiry in 2034 (assuming a 20-year term from filing). Similar patent filings in the antibody space peaked between 2010 and 2015, reflecting heightened R&D activity.
Patent filings tend to cluster around:
-
Antibody sequences with high binding affinity.
-
Specific formulations and conjugates.
-
Combination therapies involving the antibody and other agents.
Geographic considerations
Patent protections are primarily in the US, with counterparts filed or granted in the European Patent Office (EPO), Japan, and China. The scope varies by jurisdiction, with some countries emphasizing claims on production methods and others focused on therapeutic use.
Litigation and licensing
Some patents in this space face litigation or licensing disputes, especially over antibody sequences or epitope overlaps. The patent landscape remains active, with strategic claims on novel antibodies and methods used to block competitors' advancements.
Patent expiration impact
Once the patent expires, generic or biosimilar versions of the antibody can enter the market, expanding access and lowering prices. The current term expiry in 2034 provides a window for marketing and licensing strategies.
Summary table: Patent Landscape Highlights
| Aspect |
Details |
| Filing date |
2014 |
| Issue date |
2019 |
| Expiry date |
2034 (assuming 20-year term) |
| Primary focus |
Monoclonal antibody targeting specified epitope with therapeutic use |
| Key competitors |
Regeneron, Amgen, Genentech, others |
| Related patents |
Multiple related patents on antibody sequences and formulations |
| Filing jurisdictions |
US, Europe, Japan, China |
| Litigation status |
Ongoing or potential, depending on overlapping claims |
Key Takeaways
-
Patent 9,463,179 covers a monoclonal antibody targeting a designated epitope, with claims encompassing compositions, methods, and manufacturing.
-
Its scope includes antibody sequences with specified binding characteristics, along with formulations and uses.
-
The patent landscape features numerous patents on similar targets, with active litigation and licensing.
-
Expiry is projected for 2034, creating opportunities and risks for biosimilar developers and originator companies.
-
Strategic patent positioning relies on differentiating antibody sequences, formulations, and therapeutic methods.
FAQs
Q1: Does patent 9,463,179 cover all antibodies against the same target?
No. It covers specific antibody sequences and binding properties. Other antibodies with different sequences or binding epitopes may not infringe.
Q2: Can a competing company develop a similar antibody with different amino acid sequences?
Potentially, if the new antibody does not fall within the scope of the patent claims, especially if it binds different epitopes or has different sequences.
Q3: Are manufacturing methods protected under this patent?
Yes, some claims address recombinant production methods, adding a layer of protection.
Q4: How does this patent influence biosimilar development?
It restricts biosimilar development until expiry in 2034 unless challenged successfully or designed around.
Q5: What strategic actions can patent holders take?
Filing continuing applications, patenting related formulations, and securing patents in key jurisdictions extend market exclusivity.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 9,463,179.
[2] WIPO. (2023). Patent Landscape Report on Antibodies.
[3] patentScope. (2023). Patent family data for similar antibody patents.
